Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 16/20 | 0.78 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.78 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7288262 | 0.93 | ADRB3 (0.69) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7297780 | 0.92 | ADRB3 (0.68) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7296273 | 0.91 | ADRB3 (0.67) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7285328 | 0.91 | ADRB3 (0.67) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6056296 | 0.85 | HTR1A (0.71) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7884160 | 0.82 | ADRB3 (0.60) | ADRB3ADRB1ADRB2 | |
| SCHEMBL16549970 | 0.81 | ADRB2 (0.70) | ADRB3ADRB1ADRB2 | |
| SCHEMBL17946309 | 0.81 | ADRB2 (0.62) | ADRB3ADRB1ADRB2 | |
| Hydrochloric Acid SCHEMBL6539677 | 0.81 | ADRB3 (0.76) | ADRB3ADRB1ADRB2 | |
| SCHEMBL4845543 | 0.81 | HTR1A (0.76) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6169105-B1 | POTENTIATING THE ACTION OF PAROXETINE IN INCREASING THE AVAILABILITY OF SEROTONIN, NOREPINEPHRINE AND DOPAMINE IN THE BRAIN BY ADMINISTERING PAROXETINE TO A PATIENT IN NEED THEREOF IN COMBINATION WITH WAY 100635 | ELI LILLY AND COMPANY | 2001-01-02 | — | — | US | disclosed |
| EP-0759299-B1 | Potentiation of serotonin response | LILLY CO ELI (US) | 2000-04-26 | — | — | EP | disclosed |
| US-5958429-A | TREATING DEPRESSION | ELI LILLY AND COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| US-5776969-A | MIXTURE OF ANTISEROTONIN AGENT AND SEROTONIN RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1997031629-A1 | TREATMENT OF SLEEP DISORDERS | ELI LILLY AND COMPANY (US) | 1997-09-04 | — | — | WO | disclosed |
| EP-0792649-A1 | Treatment of sleep disorders | ELI LILLY AND COMPANY (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1997006792-A1 | POTENTIATION OF SEROTONIN RESPONSE | ELI LILLY AND COMPANY (US) | 1997-02-27 | — | — | WO | disclosed |
| EP-0759299-A1 | Potentiation of serotonin response | ELI LILLY AND COMPANY (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5552429-A | ADMINISTERING FLUOXETINE AND PINDOLOL TO INCREASE AVAILABILITY OF SEROTONIN, DOPAMINE AND NOREPINEPHRINE | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| US-5538992-A | SEROTONIN RECEPTOR ANTAGONIST AND FLUOXETINE FOR INCONTIENCE AND ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1996-07-23 | — | — | US | disclosed |
| US-5532264-A | POTENTIATION OF VENLAFAXINE, MILNACIPRAN AND DULOXETINE TO INCREASE AVAILABLE SEROTONIN, NOREPINEPHRINE AND DOPAMINE IN THE BRAIN BY ADMINISTERING OXYALKYLAMINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5532250-A | ADMINISTERING A SEROTONIN 1A RECEPTOR ANTAGONIST: ALPRENOLOL, PINDOLOL, PROPRANOLOL, OR TERTATOLOL, WITH FLUOXETINE, VENLAFAXINE, MILNACIPRAN RO DULOXETINE | ELI LILLY AND COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5532244-A | Potentiation of drug response | ELI LILLY AND COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5532268-A | INCREASING THE SEROTONIN, NOREPINEPHRINE AND DOPAMINE IN THE BRAIN USING FLUOXETINE AND ALPRENOLOL, SPIPERONE, TETRATOLOL AND PROPRANOLOL | ELI LILLY AND COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| EP-0714663-A2 | Potentiation of drug response by a serotonin 1A receptor antagonist | ELI LILLY AND COMPANY (US) | 1996-06-05 | — | — | EP | disclosed |
| EP-0687472-A2 | Potentiation of drug response by a serotonin 1A receptor antagonist | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | disclosed |
| EP-0642787-A2 | Cessation of tobacco use | ELI LILLY AND COMPANY (US) | 1995-03-15 | — | — | EP | disclosed |